SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis
- PMID: 40544703
- DOI: 10.1016/j.virol.2025.110607
SARS-CoV-2 host-pathogen interactome: insights into more players during pathogenesis
Abstract
SARS-CoV-2, the virus responsible for COVID-19, emerged in December 2019 and was declared a global health emergency in January 2020. The pandemic has led to nearly 7 million deaths worldwide, prompting ongoing research into viral variants and potential future outbreaks. Like other viruses, SARS-CoV-2 relies on host proteins to complete its life cycle, hijacking cellular processes to enhance replication and evade immune responses. The virus primarily enters host cells through the angiotensin-converting enzyme 2 (ACE2) receptor, but additional co-receptors, including C-type lectins, neuropilin-1, basigin (CD147), and tyrosine-protein kinase receptors, may also facilitate entry. To evade immune detection, SARS-CoV-2 targets the type I interferon (IFN) pathway, disrupting antiviral responses. Viral replication is supported by interactions with host polymerase (Pol δ), lipid droplet regulators, and Ras-related proteins. Non-structural proteins (NSPs) further manipulate host ATP metabolism and stress response pathways in the endoplasmic reticulum (ER) and mitochondria. The membrane (M) protein plays a crucial role in viral trafficking, interacting with host proteins to direct assembly at the ER-Golgi intermediate compartment (ERGIC) or plasma membrane, promoting syncytia formation. For viral release, SARS-CoV-2 exploits tight junction proteins, enhancing its spread within the lungs. This narrative review unpacks the SARS-CoV-2 host-pathogen interactome, highlighting critical structural and non-structural protein interactions as well as crucial host proteins that are expressed during the pathogenesis process. Through an integrative perspective of essential "players" during pathogenesis, this review aims to uncover therapeutic and vaccine targets, offering insights into antiviral strategies against SARS-CoV-2 and future coronaviruses.
Keywords: COVID-19; Interactome; Pathogenesis; Protein-protein interaction (PPI); SARS-CoV-2.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
The Tetraspanin CD9 Facilitates SARS-CoV-2 Infection and Brings Together Different Host Proteins Involved in SARS-CoV-2 Attachment and Entry into Host Cells.Viruses. 2025 Aug 20;17(8):1141. doi: 10.3390/v17081141. Viruses. 2025. PMID: 40872854 Free PMC article.
-
Host protein ARF1 is a proviral factor for SARS-CoV-2 and a candidate broad-spectrum therapeutic target.Nat Commun. 2025 Jul 9;16(1):6326. doi: 10.1038/s41467-025-61431-8. Nat Commun. 2025. PMID: 40634337 Free PMC article.
-
Determinants of susceptibility to SARS-CoV-2 infection in murine ACE2.J Virol. 2025 Jun 17;99(6):e0054325. doi: 10.1128/jvi.00543-25. Epub 2025 May 12. J Virol. 2025. PMID: 40353671 Free PMC article.
-
SARS-CoV-2-associated lymphopenia: possible mechanisms and the role of CD147.Cell Commun Signal. 2024 Jul 4;22(1):349. doi: 10.1186/s12964-024-01718-3. Cell Commun Signal. 2024. PMID: 38965547 Free PMC article. Review.
-
Physical interventions to interrupt or reduce the spread of respiratory viruses.Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6. Cochrane Database Syst Rev. 2023. PMID: 36715243 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous